Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$75.09Cboe Real-Time Last Sale as of 11:21AM ET 1/18/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-3.27(4.17%)
Bid (Size)$74.90 (119)
Ask (Size)$75.18 (5)
Day Low / High$74.58 - 76.58
Volume228.1 K
 

View Biotechnology IndustryPeer Comparison as of 01/18/2022

 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $75.09
Change: -3.27 (4.17%)
Volume: 228.1 K
11:21AM ET 1/18/2022
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $117.58
Change: -6.73 (5.41%)
Volume: 159.2 K
11:21AM ET 1/18/2022
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $85.90
Change: -5.47 (5.99%)
Volume: 545.7 K
11:21AM ET 1/18/2022
 
 

Novavax Inc ( NASDAQ )

Price: $101.93
Change: -8.89 (8.02%)
Volume: 2.0 M
11:21AM ET 1/18/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

RBC Downgrades Neurocrine Biosciences to Sector Perform From Outperform, Sees 2022 as 'Investment Year' With Fewer Upside Catalysts, Cuts Price Target to $90 From $122
8:58AM ET 1/18/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...

Xenon Pharmaceuticals Says Partner Neurocrine Biosciences Hits Regulatory Milestone in Epilepsy Collaboration
9:01AM ET 1/12/2022 MT Newswires

Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...

RBC Capital Trims Neurocrine Biosciences' Price Target to $122 From $125 'on Ingrezza Sales Adjustments;' Outperform Rating Kept
9:36AM ET 1/07/2022 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....

Neurocrine Biosciences Preliminary Ingrezza Sales Up 25% in Q4'21
4:28PM ET 1/06/2022 MT Newswires

Neurocrine Biosciences (NBIX) on Thursday reported preliminary Ingrezza drug sales of about $301 million for Q4 and about $1.1 billion for the full year...

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Phone+1.858.617.7600
Number of Employees585
Recent SEC Filing01/12/20224
Chief Executive Officer & DirectorKevin Charles Gorman
Vice President-Information Technology & OperationsBill Wilson
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis

Company Highlights

Price Open$75.41
Previous Close$78.36
52 Week Range$71.88 - 120.27
Market Capitalization$7.1 B
Shares Outstanding94.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings17.15
Earnings per Share$4.83
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin41.59%
Return on Equity35.89%

Analyst Ratings as of 01/14/2022

Buy
14
Overweight
2
Hold
10
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset